(Q42237739)

19 October 2017

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. (English)

1 reference

19 October 2017

1 reference

1 reference

1 reference

3

Christophe Hézode

0 references

Stefan Zeuzem

10

object named as

Stefan Zeuzem

1 reference

19 October 2017

Gregory Everson

1

1 reference

19 October 2017

Curtis Cooper

2

1 reference

19 October 2017

Christophe Hézode

3

1 reference

19 October 2017

Mitchell L Shiffman

4

1 reference

19 October 2017

Eric Yoshida

5

1 reference

19 October 2017

Teresita Beltran-Jaramillo

6

1 reference

19 October 2017

Pietro Andreone

7

1 reference

19 October 2017

Savino Bruno

8

1 reference

19 October 2017

Peter Ferenci

9

1 reference

19 October 2017

Michael Brunda

11

1 reference

19 October 2017

Sophie Le Pogam

12

1 reference

19 October 2017

Isabel Nájera

13

1 reference

19 October 2017

Julian Zhou

14

1 reference

19 October 2017

Mercidita T Navarro

15

1 reference

19 October 2017

Athina Voulgari

16

1 reference

19 October 2017

Nancy S Shulman

17

1 reference

19 October 2017

Ellen S Yetzer

18

1 reference

19 October 2017

12 February 2014

1 reference

19 October 2017

1 reference

19 October 2017

35

1 reference

19 October 2017

1

1 reference

19 October 2017

108-119

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

19 October 2017

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems

21 January 2018

1 reference

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

21 January 2018

1 reference

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

21 January 2018

1 reference

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

Two-sided confidence intervals for the single proportion: comparison of seven methods

21 January 2018

1 reference

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

21 January 2018

1 reference

Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads

21 January 2018

1 reference

Probable Inference, the Law of Succession, and Statistical Inference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12471

1 reference

release_vjswbfullrfkfjrccttppfzzne

19 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vjswbfullrfkfjrccttppfzzne

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference